Company Announcement: Quest Diagnostics' CEO Jim Davis will discuss the company's strategy and market trends at the Baird 2025 Global Healthcare Conference on September 10, 2025, with a live webcast available on their investor relations page.
About Quest Diagnostics: The company provides diagnostic insights to improve health outcomes and serves a significant portion of the U.S. population, emphasizing its role in healthcare management and disease treatment.
DGX
$178.66+Infinity%1D
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
7 Hold
0 Sell
Moderate Buy
Current: 184.110
Low
190.00
Averages
200.78
High
215.00
Current: 184.110
Low
190.00
Averages
200.78
High
215.00
Piper Sandler
Neutral
maintain
$190 -> $200
2025-10-27
Reason
Piper Sandler
Price Target
$190 -> $200
2025-10-27
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Quest Diagnostics to $200 from $190 following quarterly results. The firm keeps a Neutral rating on the shares.
Morgan Stanley
Erin Wright
Overweight
maintain
$191 -> $207
2025-10-22
Reason
Morgan Stanley
Erin Wright
Price Target
$191 -> $207
2025-10-22
maintain
Overweight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Quest Diagnostics (DGX) to $207 from $191 and keeps an Overweight rating on the shares. Another "beat & raise" quarter was "encouraging," but shares slid as expectations were high and margin pressure was seen in Q3. The firm, which cites a "robust" utilization environment and relative policy insulation for its hiked target, thinks utilization strength should be a positive read for Labcorp's (LH) upcoming report on October 28, but notes that the bar may be raised for labs.
Truist
Hold
maintain
$195 -> $205
2025-10-22
Reason
Truist
Price Target
$195 -> $205
2025-10-22
maintain
Hold
Reason
Truist raised the firm's price target on Quest Diagnostics to $205 from $195 and keeps a Hold rating on the shares. The company posted solid Q3 results ahead of consensus expectations on the top and bottom-lines with FY25 nudged higher as its core trends remain solid with organic volumes ahead of the firm's thinking, better revenue, and a continued tailwind from testing, with the organic revenue guide raised, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$190 -> $195
2025-10-22
Reason
Barclays
Price Target
$190 -> $195
2025-10-22
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Quest Diagnostics to $195 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company reported "another solid print," the analyst tells investors in a research note. The firm views the post-earnings share selloff as a function of investor positioning given the strength in core tools names and improving sentiment versus moving away from the more defensive labs.
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
